Physician profile
Mie Fowler
NPI 1396222782
$1,790.76
in general payments reported to CMS, 2019-2025
17 companies · $782 in 2025
The $782 reported for 2025 was more than what 81% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $108 · 2022: $300 · 2023: $216 · 2024: $386 · 2025: $782.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,206 · Education: $177.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,205.92 |
| Education | $176.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $429.72 | 2022-2025 | Jakafi, Niktimvo |
| Janssen Biotech, INC. | $165.07 | 2022-2025 | Rybrevant, Erleada |
| Myriad Genetic Laboratories, INC. | $140.72 | 2021-2022 | |
| Caris Mpi, INC. | $127.92 | 2025 | Mi Cancer Seek |
| Gilead Sciences, INC. | $125.81 | 2024 | Trodelvy |
| Agios Pharmaceuticals, INC. | $124.96 | 2025 | Pyrukynd |
| Pfizer INC. | $120.78 | 2025 | |
| Emd Serono, INC. | $108.67 | 2025 | |
| Glaxosmithkline, LLC. | $103.64 | 2024 | Ojjaara |
| Seagen INC. | $77.99 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $77.84 | 2022-2025 | Libtayo, Dupixent |
| Astrazeneca Pharmaceuticals LP | $64.77 | 2024-2025 | Imfinzi, Enhertu |
| Eisai INC. | $46.39 | 2025 | |
| Daiichi Sankyo INC. | $25.05 | 2025 | Vanflyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.13 | 2025 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $15.00 | 2025 | Reblozyl |
| Merck Sharp & Dohme LLC | $14.30 | 2024 | Keytruda, Welireg, Lynparza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mie Fowler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.